Mapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants
- 1Institut Imagine, Paris, France; Necker Sick Children Hospital, Paris, France
Abstract
Deep intronic variants remain an understudied class of pathogenic variation, primarily due to their absence from standard exome and gene panel datasets and the complexity of non-coding genome interpretation. We hypothesized that pathogenic deep intronic variants are not randomly distributed but instead cluster within intronic "hotspots" inherently prone to pseudoexon activation, and that mapping such regions could improve molecular diagnosis. Importantly, such intronic hotspots nominate targets for antisense oligonucleotide (ASO) therapy. Using X-linked Alport syndrome as a proof-of-concept model and based on our previous work, we screened unsolved patients across multiple European diagnostic centers for variants within a defined region of COL4A5 intron 6. We identified eight independent variants in more than 35 affected individuals from ten unrelated families, which led to two pseudoexon inclusion events, both using the same strong cryptic splice donor site. In all, RNA sequencing and/or minigene assays confirmed aberrant splicing, even when prediction tools were discordant or fell below clinical thresholds. A single ASO targeting the shared donor site restored normal COL4A5 mRNA and 5(IV) collagen protein expression in patient-derived cells regardless of the causative variant. Extending this analysis gene-wide using the AlphaGenome sequence-to-function model, we confirmed intron 6 as one of the most critical COL4A5 splicing hotspot and identified additional potential hotspots harboring novel predicted spliceogenic variants. This gene-agnostic framework establishes a systematic strategy for identifying intronic mutational hotspots and matching patients to scalable, mutation-agnostic ASO-based precision therapies.
Significance StatementDeep intronic variants are an underrecognized cause of genetic disease, undetectable to standard exome and gene-panel testing and difficult to interpret. Using X-linked Alport syndrome as an exemplar, we identified a recurrent deep intronic mutational hotspot in which independent pathogenic variants from unrelated families converge on the same cryptic splice donor site to activate pseudoexon inclusion. A single antisense oligonucleotide therapy corrected this shared splicing defect and restored normal collagen IV protein production in patient cells, regardless of the underlying causative variant. Extending this analysis gene-wide using an AlphaGenome sequence-to-function splicing model, we uncovered additional deep intronic hotspots across the gene, establishing a gene-agnostic strategy for systematically identifying hidden pathogenic variants and matching patients to mutation-agnostic, RNA-based precision therapies in Mendelian disorders.
Related
- An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models
- Gene-Specific Antisense Oligonucleotide Therapy Targeting AMA1: A Potential Malaria Treatment.
- Population-scale genome-wide prioritization of targets for allele-specific antisense oligonucleotide therapy design
- Recurring and isolated intronic FGFR1 variants as an underdiagnosed cause of congenital hypogonadotropic hypogonadism
- Case Report: A novel intronic FRMD7 variant associated with X-linked infantile nystagmus: functional validation by a minigene splicing assay
BibTeX
@misc{saei2026mapping,
title = {{Mapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants}},
author = {H. Saei and B. Ardin and N. Kaiser and M. Ouahmane and O. Gribouval and V. Moriniere and M. Mautret-Godefroy and F. J. Wopperer and K. M. Riedhammer and D. P. Gale and O. Sadeghi-Alavijeh and C. Goursaud and O. Grunewald and C. Prosper and L. Lebreton and M. Rabant and C. Bergmann and R. Kormann and S. Decramer and B. Knebelmann and C. Antignac and M. S. Wiesener and G. Dorval},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.10.26362533},
url = {https://www.medrxiv.org/content/10.64898/2026.09.10.26362533v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Mapping intronic mutational hotspots by in silico mutagenesis enables single antisense oligonucleotide correction of multiple variants
AU - H. Saei
AU - B. Ardin
AU - N. Kaiser
AU - M. Ouahmane
AU - O. Gribouval
AU - V. Moriniere
AU - M. Mautret-Godefroy
AU - F. J. Wopperer
AU - K. M. Riedhammer
AU - D. P. Gale
AU - O. Sadeghi-Alavijeh
AU - C. Goursaud
AU - O. Grunewald
AU - C. Prosper
AU - L. Lebreton
AU - M. Rabant
AU - C. Bergmann
AU - R. Kormann
AU - S. Decramer
AU - B. Knebelmann
AU - C. Antignac
AU - M. S. Wiesener
AU - G. Dorval
PY - 2026
DA - 2026/09/10
PB - medRxiv
DO - 10.64898/2026.09.10.26362533
UR - https://www.medrxiv.org/content/10.64898/2026.09.10.26362533v1
AB - Deep intronic variants remain an understudied class of pathogenic variation, primarily due to their absence from standard exome and gene panel datasets and the complexity of non-coding genome interpretation. We hypothesized that pathogenic deep intronic variants are not randomly distributed but instead cluster within intronic "hotspots" inherently prone to pseudoexon activation, and that mapping such regions could improve molecular diagnosis. Importantly, such intronic hotspots nominate targets for antisense oligonucleotide (ASO) therapy. Using X-linked Alport syndrome as a proof-of-concept model and based on our previous work, we screened unsolved patients across multiple European diagnostic centers for variants within a defined region of COL4A5 intron 6. We identified eight independent variants in more than 35 affected individuals from ten unrelated families, which led to two pseudoexon inclusion events, both using the same strong cryptic splice donor site. In all, RNA sequencing and/or minigene assays confirmed aberrant splicing, even when prediction tools were discordant or fell below clinical thresholds. A single ASO targeting the shared donor site restored normal COL4A5 mRNA and 5(IV) collagen protein expression in patient-derived cells regardless of the causative variant. Extending this analysis gene-wide using the AlphaGenome sequence-to-function model, we confirmed intron 6 as one of the most critical COL4A5 splicing hotspot and identified additional potential hotspots harboring novel predicted spliceogenic variants. This gene-agnostic framework establishes a systematic strategy for identifying intronic mutational hotspots and matching patients to scalable, mutation-agnostic ASO-based precision therapies. Significance StatementDeep intronic variants are an underrecognized cause of genetic disease, undetectable to standard exome and gene-panel testing and difficult to interpret. Using X-linked Alport syndrome as an exemplar, we identified a recurrent deep intronic mutational hotspot in which independent pathogenic variants from unrelated families converge on the same cryptic splice donor site to activate pseudoexon inclusion. A single antisense oligonucleotide therapy corrected this shared splicing defect and restored normal collagen IV protein production in patient cells, regardless of the underlying causative variant. Extending this analysis gene-wide using an AlphaGenome sequence-to-function splicing model, we uncovered additional deep intronic hotspots across the gene, establishing a gene-agnostic strategy for systematically identifying hidden pathogenic variants and matching patients to mutation-agnostic, RNA-based precision therapies in Mendelian disorders.
ER -